

recurrence avoided is €82 in the 5 years time horizon and the open mesh is the dominant option in the 15 years time horizon from a hospital perspective. Results in the probability sensitivity analysis are very similar to deterministic analysis. **CONCLUSION:** Findings suggest open mesh hernia repair method as a very cost effective therapy from both hospitals and payers perspectives for the inguinal hernia treatment in Slovakia.

PHC9

THE POTENTIAL SAVINGS IN OPERATING ROOM TIME ASSOCIATED WITH THE USE OF SUGAMMADEX TO REVERSE SELECTED NEUROMUSCULAR BLOCKING AGENTS: FINDINGS FROM A HOSPITAL EFFICIENCY MODEL

Zhang B¹, Menzin J¹, Tran MH², Neumann PJ³, Friedman M¹, Sussman M¹, Hepner D⁴

¹Boston Health Economics, Inc, Waltham, MA, USA, ²Organon International, a part of Schering-Plough Corporation, Roseland, NJ, USA, ³Tufts-New England Medical Center, Boston, MA, USA, ⁴Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
OBJECTIVE: Operating rooms (OR) are an expensive hospital resource. As a new selective reversal binding agent, sugammadex has been shown in clinical trials to reduce reversal time (time from reversal agent administration to full recovery) among patients receiving selected steroidal neuromuscular-blocking agents (NMBAs). Our goal was to develop a hospital efficiency model to assess the potential impact of sugammadex adoption on OR time. **METHODS:** A deterministic model was developed to estimate potential time savings associated with sugammadex adoption for the U.S. setting. Model inputs included surgical caseloads, utilization rates of NMBAs and reversal strategies, OR time components, and OR labor costs. The effects of reversal strategies on reversal time were evaluated using clinical trial data. Other model inputs were estimated using published literature and analyses of secondary hospital databases. OR time saved was defined as the difference in minutes required for all procedures performed per day in one OR before and after the introduction of sugammadex. Estimates of savings in OR staff costs (including OR nurse, OR technician, and certified registered nurse anesthetist) were generated under alternative assumptions about the likelihood that overtime is paid. Sensitivity analyses were performed on key model assumptions. **RESULTS:** In the base-case scenario, OR time saved by sugammadex was estimated to be 25 minutes per OR day or 612 hours annually in a typical US hospital with 6 ORs. Associated annual cost savings were estimated to range from \$32,035 (25% of days involve overtime) to \$96,105 (75% of days involve overtime). Findings also varied with the assumed adoption rate of sugammadex and hourly OR staff salaries. **CONCLUSION:** Sugammadex may save OR time and associated costs for U.S. hospitals, primarily by reducing overtime pay. The net financial benefit of sugammadex will depend on its cost and its adoption rate in clinical practice.

PHC10

AN ASSESSMENT OF HOSPITAL COSTS AND REIMBURSEMENT AMONG TOTAL HIP OR KNEE ARTHROPLASTY PATIENTS IN THE UNITED STATES THAT EXPERIENCE VENOUS THROMBOEMBOLISM

Song X¹, Sander S², Huse D¹, Harris K², Amin AN³

¹Thomson Healthcare Inc, Cambridge, MA, USA, ²Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, USA, ³University of California, Irvine, Irvine, CA, USA

OBJECTIVE: Deep vein thrombosis (DVT) and pulmonary embolism (PE), collectively known as venous thromboembolism (VTE), are well-known complications of total knee or hip

arthroplasty (TKA and THA). This study examined the economic burden of VTE in arthroplasty surgeries from a US hospital perspective. **METHODS:** Patients at least 18 years old undergoing TKA and THA from January 1, 2002 to December 30, 2006 were extracted from a large, nationwide inpatient database. Rates of events, length of hospital stay, inpatient costs and reimbursed amounts (available for a small subset that could be linked to managed care data) were evaluated. Multivariate analyses were conducted on hospital costs to adjust for differences in demographic and clinical characteristics. **RESULTS:** Out of 259,524 hip and knee surgeries (mean age of 67 years), 1.0% of patients diagnosed with VTE during hospitalization (0.6% DVT only and 0.4% PE [with or without DVT]). Compared to patients without VTE, mean length of stay (LOS) for those with VTE was twice as long (8 vs. 4, $p < 0.0001$) and hospital costs were 48.0% higher (\$20,850 vs. \$14,092, $p < 0.0001$). Within the limited subset that had linked managed care claims data ($n = 5002$), mean cost of patients with VTE was 23.5% higher (\$16,877 vs. \$13,662, $p < 0.0023$); however, the amount reimbursed was on average 6.4% higher (\$14,121 vs. \$13,272, $p = 0.77$). After multivariate adjustment, DVT increased costs by \$1421 following TKA and \$3950 following THA; PE increased costs by \$2862 following TKA and \$4355 following THA ($p < 0.0001$ for all). **CONCLUSION:** Experiencing VTE complications substantially adds to the costs of TKA or THA. The increased hospital costs of patients with VTE did not appear to be adequately reimbursed. The overall economic impact of implementing prophylaxis to prevent VTE events can be projected.

**HEALTH CARE INTERVENTIONS—
Patient-Reported Outcomes**

PHC11

A SYSTEMATIC REVIEW OF STUDIES ON QUALITY OF LIFE IN ANIMALS

Poulsen Nautrup B¹, Van Vlaenderen I², Poulsen Nautrup C³

¹EAH Consulting, Juelich, Northrhine Westf, Germany, ²IMS Health, Brussels, Belgium, ³Ludwig-Maximilians-University, Munich, Germany

OBJECTIVE: The objective of this project was to review published studies on quality of life (QoL) in animals. **METHODS:** An electronic search in EMBASE including MEDLINE using the key words “quality of life” and “animals” resulted in 1588 articles. Inclusion criteria for review was study on QoL, exclusion criteria were case studies with $n < 3$, and studies in laboratory animals as proxy for humans. **RESULTS:** A total of 48 studies were included for review, of which 40 were performed in dogs. The aim of nine studies was the development and validation of a questionnaire, three studies provided a checklist or background information on QoL in animals. In the remaining 36 studies QoL was assessed as outcome measure in specific diseases or treatments; however 30 of these studies were uncontrolled. Previously developed, used or validated questionnaires were included in only 3 studies. In 23 studies assessment of QoL was limited to one single question, addressed to the owners. In 30 of the 36 studies the evaluation of QoL was performed only at one time point after the start of an intervention, of which 3 studies retrospectively evaluated a baseline value. In 19 studies, all or part of the animals were already dead at the time of assessment. In 19 of the 30 uncontrolled studies QoL was rated as good to excellent (or equivalent in scores) in $>50\%$ of the animals, even in studies on severe conditions such as cancer or chemotherapy. **CONCLUSION:** Most of the studies assessing QoL as outcome used unvalidated questionnaires and included only one single question addressed to the owners. It is questionable whether the